Literature DB >> 28067894

Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.

Robert V Rawson1,2,3, Peter A Johansson4, Nicholas K Hayward1,4, Nicola Waddell4, Ann-Marie Patch4, Serigne Lo1,2, John V Pearson4, John F Thompson1,2, Graham J Mann1,5, Richard A Scolyer1,2,3, James S Wilmott1,2.   

Abstract

Ultraviolet radiation (UVR) mutagenesis causes nearly all cutaneous melanomas, however, since UVR signatures are largely absent in acral melanoma, as well as melanoma in sun-protected sites, the cause of these melanomas is unknown. Whole-genome sequencing data generated as part of the Australian Melanoma Genome Project was supplemented with a detailed histopathological assessment with the melanomas then classified as UVR or non-UVR related, based on their mutation signatures. The clinicopathological characteristics of melanomas with mutation signatures for their subtype were compared. Three (of 35=8.6%) acral melanomas, all clinically and pathologically verified as arising from acral or subungual locations, had predominant UVR mutation burden, whereas four (of 140=2.9%) cutaneous melanomas showed predominant non-UVR mutations. Among the acral melanomas, the few that were UVR dominant occurred in younger patients, had a higher mutation load and a proportion of mutation burden due to UVR, which was similar to that in melanomas from intermittently UVR-exposed skin. Acral melanomas with a UVR signature occurred most frequently in subungual sites and included tumors harboring BRAF or NF1 mutations. Cutaneous melanomas dominated by non-UVR signatures had lower mutation burdens counts and their primary tumors were thicker and had more mitoses than in other cutaneous melanomas. No histopathological features predicted UVR dominance in acral melanomas or non-UVR dominance in cutaneous melanomas. Our finding of acral/subungual melanomas with predominant UVR mutagenesis suggests that the nail plate and acral skin do not provide complete protection from UVR. Our data also confirm that cutaneous melanomas not caused by UVR are infrequent. Identifying where mutation burden is discordant with primary tumor anatomical site is likely to be clinically significant when determining treatment options for metastatic acral and cutaneous melanoma patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28067894     DOI: 10.1038/labinvest.2016.143

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  31 in total

1.  Some geographical aspects of the mortality from melanoma in Europeans.

Authors:  H O LANCASTER
Journal:  Med J Aust       Date:  1956-06-30       Impact factor: 7.738

2.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  UV-A and UV-B penetration of normal human cadaveric fingernail plate.

Authors:  Dana K Stern; Alia Annette Creasey; John Quijije; Mark G Lebwohl
Journal:  Arch Dermatol       Date:  2010-12-20

4.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.

Authors:  Farhad Azimi; Richard A Scolyer; Pavlina Rumcheva; Marc Moncrieff; Rajmohan Murali; Stanley W McCarthy; Robyn P Saw; John F Thompson
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

5.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

6.  Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin.

Authors:  B C Bastian; M Kashani-Sabet; H Hamm; T Godfrey; D H Moore; E B Bröcker; P E LeBoit; D Pinkel
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

7.  A comprehensive catalogue of somatic mutations from a human cancer genome.

Authors:  Erin D Pleasance; R Keira Cheetham; Philip J Stephens; David J McBride; Sean J Humphray; Chris D Greenman; Ignacio Varela; Meng-Lay Lin; Gonzalo R Ordóñez; Graham R Bignell; Kai Ye; Julie Alipaz; Markus J Bauer; David Beare; Adam Butler; Richard J Carter; Lina Chen; Anthony J Cox; Sarah Edkins; Paula I Kokko-Gonzales; Niall A Gormley; Russell J Grocock; Christian D Haudenschild; Matthew M Hims; Terena James; Mingming Jia; Zoya Kingsbury; Catherine Leroy; John Marshall; Andrew Menzies; Laura J Mudie; Zemin Ning; Tom Royce; Ole B Schulz-Trieglaff; Anastassia Spiridou; Lucy A Stebbings; Lukasz Szajkowski; Jon Teague; David Williamson; Lynda Chin; Mark T Ross; Peter J Campbell; David R Bentley; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

8.  Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.

Authors:  Porcia T Bradford; Alisa M Goldstein; Mary L McMaster; Margaret A Tucker
Journal:  Arch Dermatol       Date:  2009-04

9.  Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression.

Authors:  Georgina V Long; James S Wilmott; Lauren E Haydu; Varsha Tembe; Raghwa Sharma; Helen Rizos; John F Thompson; Julie Howle; Richard A Scolyer; Richard F Kefford
Journal:  Pigment Cell Melanoma Res       Date:  2013-05-03       Impact factor: 4.693

10.  Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand.

Authors:  J L Bulliard; B Cox; J M Elwood
Journal:  Cancer Causes Control       Date:  1994-05       Impact factor: 2.506

View more
  10 in total

Review 1.  Translational pathology, genomics and the development of systemic therapies for acral melanoma.

Authors:  Yian Ann Chen; Jamie K Teer; Zeynep Eroglu; Jheng-Yu Wu; John M Koomen; Florian A Karreth; Jane L Messina; Keiran S M Smalley
Journal:  Semin Cancer Biol       Date:  2019-11-02       Impact factor: 15.707

Review 2.  Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities.

Authors:  Roy Rabbie; Peter Ferguson; Christian Molina-Aguilar; David J Adams; Carla D Robles-Espinoza
Journal:  J Pathol       Date:  2019-02-15       Impact factor: 7.996

3.  Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review.

Authors:  Qingyue Zheng; Jiarui Li; Hanlin Zhang; Yuanzhuo Wang; Shu Zhang
Journal:  Front Oncol       Date:  2020-12-03       Impact factor: 6.244

Review 4.  Cutaneous and Mucosal Melanomas of Uncommon Sites: Where Do We Stand Now?

Authors:  Emi Dika; Martina Lambertini; Cristina Pellegrini; Giulia Veronesi; Barbara Melotti; Mattia Riefolo; Francesca Sperandi; Annalisa Patrizi; Costantino Ricci; Martina Mussi; Maria Concetta Fargnoli
Journal:  J Clin Med       Date:  2021-01-28       Impact factor: 4.241

5.  Construction and validation of a prognostic risk model of angiogenesis factors in skin cutaneous melanoma.

Authors:  Songyun Zou; Yonggang Zhang; Limei Zhang; Dengchuan Wang; Shi Xu
Journal:  Aging (Albany NY)       Date:  2022-02-14       Impact factor: 5.682

6.  Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.

Authors:  Prachi Bhave; Tasnia Ahmed; Serigne N Lo; Alexander Shoushtari; Anne Zaremba; Judith M Versluis; Joanna Mangana; Michael Weichenthal; Lu Si; Thierry Lesimple; Caroline Robert; Claudia Trojanello; Alexandre Wicky; Richard Heywood; Lena Tran; Kathleen Batty; Florentia Dimitriou; Anna Stansfeld; Clara Allayous; Julia K Schwarze; Meghan J Mooradian; Oliver Klein; Inderjit Mehmi; Rachel Roberts-Thomson; Andrea Maurichi; Hui-Ling Yeoh; Adnan Khattak; Lisa Zimmer; Christian U Blank; Egle Ramelyte; Katharina C Kähler; Severine Roy; Paolo A Ascierto; Olivier Michielin; Paul C Lorigan; Douglas B Johnson; Ruth Plummer; Celeste Lebbe; Bart Neyns; Ryan Sullivan; Omid Hamid; Mario Santinami; Grant A McArthur; Andrew M Haydon; Georgina V Long; Alexander M Menzies; Matteo S Carlino
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

Review 7.  Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma.

Authors:  Jianping Gui; Zhen Guo; Di Wu
Journal:  J Transl Med       Date:  2022-08-16       Impact factor: 8.440

Review 8.  More than just acral melanoma: the controversies of defining the disease.

Authors:  Sara S Bernardes; Ingrid Ferreira; David E Elder; Aretha B Nobre; Héctor Martínez-Said; David J Adams; Carla Daniela Robles-Espinoza; Patricia A Possik
Journal:  J Pathol Clin Res       Date:  2021-07-02

9.  Patterns of genomic evolution in advanced melanoma.

Authors:  E Birkeland; S Zhang; D Poduval; J Geisler; S Nakken; D Vodak; L A Meza-Zepeda; E Hovig; O Myklebost; S Knappskog; P E Lønning
Journal:  Nat Commun       Date:  2018-07-10       Impact factor: 14.919

10.  Physical activity, cardiorespiratory fitness and risk of cutaneous malignant melanoma: Systematic review and meta-analysis.

Authors:  Gundula Behrens; Tobias Niedermaier; Mark Berneburg; Daniela Schmid; Michael F Leitzmann
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.